Anti-Mouse CD47/IAP Antibody (MIAP301) is a monoclonal antibody inhibitor targeting mouse CD47/IAP. It enhances macrophage phagocytosis and immune cell infiltration, restores myeloid cell phagocytic function, and alleviates B-cell suppression. It can be used in research on cancer, inflammation, and infectious diseases.

Anti-Mouse CD47/IAP Antibody (MIAP301) (10 μg/mL, 24 hours) can significantly inhibit the migration ability of epithelial cells and delay the wound closure process [1].
Anti-Mouse CD47/IAP Antibody (MIAP301) (25 μg/mL, 2-4 hours) can significantly enhance the phagocytic activity of macrophages against SM1 cells [2].
Anti-Mouse CD47/IAP Antibody (MIAP301) (8 hours) can effectively restore the phagocytic capacity of myeloid cells against Escherichia coli [3].

In a biopsy-derived mucosal wound model of male C57Bl/6J mice, a single intraperitoneal injection of 400 μg Anti-Mouse CD47/IAP Antibody (MIAP301) at 24 hours post-operation significantly inhibited mucosal wound healing [1].
Similarly, in female C57BL/6 mice bearing SM1 or B16F10 tumors, intratumoral injection of Anti-Mouse CD47/IAP Antibody (MIAP301) at a dose of 100 μg (administered every three days until study termination) in combination with Nexturastat A significantly suppressed tumor growth and enhanced immune cell infiltration in the tumor microenvironment [2].
For Klebsiella pneumoniae-induced septicemia in Balb/c or C57/BL6 mice, a single intravenous injection of 2.5 mg/kg Anti-Mouse CD47/IAP Antibody (MIAP301) at 1 hour or 8 hours after cecal ligation and puncture (CLP) surgery significantly reduced bacterial load in the blood and organs while improving mouse survival rates [3].

MIAP301

Mouse

Monoclonal

Unconjugated